Mdm2

Rain Therapeutics to Report Second Quarter 2021 Financial Results and Highlights of Recent Progress on August 10, 2021

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Biology, Proteins, Genetics, Synthetic lethality, Mdm2, Cancer

NEWARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN) a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the second quarter that ended June 30, 2021 and highlights of recent progress, on Tuesday, August 10, 2021.

Key Points: 
  • NEWARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN) a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the second quarter that ended June 30, 2021 and highlights of recent progress, on Tuesday, August 10, 2021.
  • On that day, management will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m.
  • Rains lead product candidate, milademetan (RAIN-32), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers.
  • In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Proteins, Tumor suppressor genes, Apoptosis, P53, Programmed cell death, Bert Vogelstein, Mdm2

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.

Key Points: 
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.
  • p53 mutations are found in approximately half of all cancers.
  • The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979.
  • Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Rain Therapeutics Announces Collaboration with Tempus for Genomic Analysis in Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32

Retrieved on: 
Thursday, June 3, 2021
Branches of biology, Genetics, Synthetic lethality, Precision medicine, Mdm2

NEWARK, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, today announceda master program and a genomic analysis platform agreement for comprehensive genomic profiling tests utilizing artificial intelligence and precision medicine company Tempus genomic analysis platform.

Key Points: 
  • NEWARK, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, today announceda master program and a genomic analysis platform agreement for comprehensive genomic profiling tests utilizing artificial intelligence and precision medicine company Tempus genomic analysis platform.
  • We are excited to enhance our tumor agnostic, MDM2-amplified basket trial strategy through this collaboration with Tempus, a company that shares our patient-centric mission, said Robert Doebele, M.D., Ph.D., cofounder and chief scientific officer at Rain Therapeutics.
  • We look forward to collaborating with Rain Therapeutics on their exciting Phase 2 asset, RAIN-32, and making this trial option available to patients facing MDM2-amplified cancer.
  • In addition to RAIN-32, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.For more information, visit www.rainthera.com .

Rain Therapeutics Announces Patient Referral Partnership for the Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32

Retrieved on: 
Wednesday, June 2, 2021
Branches of biology, Caris, Mdm2, Liposarcoma, Biology

NEWARK, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (Rain), a clinical-stage company developing precision oncology therapeutics, today announceda patient referral partnership with Caris Life Sciences (Caris).

Key Points: 
  • NEWARK, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (Rain), a clinical-stage company developing precision oncology therapeutics, today announceda patient referral partnership with Caris Life Sciences (Caris).
  • Rain in-licensed RAIN-32 in September 2020 based on the results of a Phase 1 clinical trial, which demonstrated meaningful antitumor activity in an MDM2-amplified subtype of liposarcoma (LPS) and other solid tumors.
  • Caris Pharmatech Just-In-Time Clinical Trial Solutions focus on rapid site activation and patient enrollment to streamline the drug development process.
  • We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

PMV Pharmaceuticals Announces Participation at the Cowen 41st Annual Health Care Conference

Retrieved on: 
Tuesday, February 23, 2021
Branches of biology, Proteins, Tumor suppressor genes, Cell biology, Biology, Apoptosis, P53, Programmed cell death, Bert Vogelstein, Mdm2

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.

Key Points: 
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.
  • p53 mutations are found in approximately half of all cancers.
  • The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979.
  • Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board

Retrieved on: 
Tuesday, February 16, 2021
Branches of biology, Proteins, Tumor suppressor genes, Mdm2, Oncogenes, P53, Tumor suppressor, MDM4, USP7, Mir-605 microRNA precursor family

"Gigis work in p53 biology has had a tremendous impact on our fundamental understanding of the p53 pathway and the consequences of p53 mutations in cancer, said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma.

Key Points: 
  • "Gigis work in p53 biology has had a tremendous impact on our fundamental understanding of the p53 pathway and the consequences of p53 mutations in cancer, said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma.
  • Dr. Guillermina (Gigi) Lozano is a geneticist recognized for her studies of the p53 tumor suppressor pathway, from characterizing p53 as a transcriptional activator to characterizing the physiological importance of Mdm2 and Mdm4 proteins as inhibitors of p53, and the consequences of p53 mutations on tumor development.
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.
  • Bringing together leaders in the field to exploit over four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus.

Ascentage Pharma Enters into an Agreement with University of Michigan to obtain an exclusive license for a MDM2 Degrader using PROTAC Technology

Retrieved on: 
Monday, November 30, 2020
Branches of biology, Proteins, Mdm2, Oncogenes, Biology, Life sciences, Proteolysis targeting chimera

Through structure-function studies of their previously discovered MDM2 inhibitors using the PROTAC technology, Dr. Wang's research team has obtained potent and efficacious MDM2 degraders that could effectively induce rapid degradation of MDM2.

Key Points: 
  • Through structure-function studies of their previously discovered MDM2 inhibitors using the PROTAC technology, Dr. Wang's research team has obtained potent and efficacious MDM2 degraders that could effectively induce rapid degradation of MDM2.
  • The lead MDM2 degrader has achieved complete and durable tumor regression in a xenograft tumor model in mice3.
  • The technology has received tremendous interest for its ability to target undruggable proteins," said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma.
  • Ascentage Pharma (6855.HK) is a globally, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and age-related diseases.

Nurix Therapeutics to Present Preclinical Data at Upcoming 5th Medicinal Chemistry & Protein Degradation Summit and 62nd ASH Annual Meeting and Exposition

Retrieved on: 
Wednesday, November 4, 2020
Branches of biology, Proteins, Post-translational modification, Apoptosis, Organelles, Proteasome, Ubiquitin ligase, Ubiquitin, CBLL1, Mdm2

SAN FRANCISCO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, todayannouncedthat it will present data on its novel targeted protein degradation platform at the upcoming 5th Medicinal Chemistry & Protein Degradation Summit and preclinical data from its lead program, NX-2127, for the potential treatment of B-cell malignancies, at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

Key Points: 
  • SAN FRANCISCO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, todayannouncedthat it will present data on its novel targeted protein degradation platform at the upcoming 5th Medicinal Chemistry & Protein Degradation Summit and preclinical data from its lead program, NX-2127, for the potential treatment of B-cell malignancies, at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
  • Nurixs drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.
  • Nurixs wholly owned pipeline comprises targeted protein degraders of Brutons tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation.
  • Nurix is headquartered in San Francisco, California.

Rain Therapeutics Announces a Phase 1 Trial Update for the MDM2 Inhibitor, RAIN-32, at the 32nd EORTC-NCI-AACR Virtual Symposium

Retrieved on: 
Monday, October 26, 2020
Branches of biology, Mdm2, Oncogenes, Proteins

"We are pleased to highlight these positive data, said Avanish Vellanki, co-founder and chief executive officer of Rain.

Key Points: 
  • "We are pleased to highlight these positive data, said Avanish Vellanki, co-founder and chief executive officer of Rain.
  • "These analyses of the Phase 1 study demonstrate the opportunity for RAIN-32 to provide safe and effective MDM2 inhibition.
  • The Phase 1 dose escalation and expansion study evaluated RAIN-32 across four dose schedules in patients (n=107) with liposarcoma, solid tumors or lymphomas.
  • Rain Therapeutics Inc. is a privately held biotechnology company developing targeted therapies for patients with cancer.

Aileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotective Therapy ALRN-6924 Being Presented at EORTC-NCI-AACR Annual Symposium

Retrieved on: 
Tuesday, October 20, 2020
Branches of biology, Cancer, Proteins, Mdm2, Oncogenes, Antineoplastic drugs, Apoptosis, Programmed cell death, European Organisation for Research and Treatment of Cancer, Chemotherapy, P53, Stapled peptide

As previously announced by Aileron, the Phase 1b clinical data will be presented in a late-breaking poster presentation during the upcoming 32nd EORTC-NCI-AACR Annual (ENA 2020) Symposium on Molecular Targets and Cancer Therapeutics, being held virtually October 24 25, 2020.

Key Points: 
  • As previously announced by Aileron, the Phase 1b clinical data will be presented in a late-breaking poster presentation during the upcoming 32nd EORTC-NCI-AACR Annual (ENA 2020) Symposium on Molecular Targets and Cancer Therapeutics, being held virtually October 24 25, 2020.
  • The abstract entitled, Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDM2/MDMX inhibitor ALRN-6924, (LBA96) will be presented starting Saturday, October 24 at 10:00 a.m. CEST (4:00 a.m.
  • A live audio webcast of Ailerons conference call will be available on the Investors section of Ailerons website at https://investors.aileronrx.com/events-presentations .
  • Our long-term vision is to bring chemoprotection to patients with p53-mutated cancers approximately 50% of cancer patients regardless of cancer type or chemotherapy.